ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1266

Time-course Ultrasonography to Predict Flare After Discontinuation of Biologics in Patients with Rheumatoid Arthritis Achieving Stringent Remission

Takehisa Ogura1, Takaharu Katagiri2, Yuto Takakura3, Chihiro Imaizumi4 and Hideto Kameda4, 1Toho university, Meguro-ku, Japan, 2Toho University School of Medicine (Ohashi Medical Center), Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 3Toho University, Setagayaku, Japan, 4Toho University, Tokyo, Japan

Meeting: ACR Convergence 2022

Keywords: Imaging, rheumatoid arthritis, Ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Imaging of Rheumatic Diseases Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Ultrasonography (US) has been suggested to be useful in predicting flare in patients with rheumatoid arthritis (RA) after discontinuation of biological disease-modifying antirheumatic drugs (bDMARDs). This study aimed to investigate whether US can predict flare after discontinuation of bDMARDs in RA patients who have achieved stringent remission criteria.

Methods: We prospectively enrolled RA patients who maintained a simplified disease activity index ≤ 3.3 and discontinued bDMARDs and measured clinical assessment and US every 2-3 months for 2 years. The US examination was performed on 40 joints using the semi-quantitative method of 0-3 on the Grey-scale (GS) and Power Doppler (PD), and the total values for each patient were used as the GS score and PD score. Joints graded as GS score ≥ 2 or PD score ≥ 1 were counted as US arthritis. In addition, tendons at 36 sites were counted with or without tendinitis/tenosynovitis to obtain a tendon score.

Results: Thirty-six patients were enrolled and two patients who dropped out early without flare were excluded from the comparative analyses. At baseline, the median GS score was 7, PD score was 0, US arthritis was 0, and tendon score was 0. The total PD score was 0 in 26 patients (72%) and it was 1 in 5 patients (14%). There were no significant differences in US findings between the relapse group (20 patients) and the non-relapse group (14 patients). Although a Cox proportional hazards model with baseline US findings showed no significant findings, using a time-dependent Cox proportional hazards model to analyze time-course US findings, the PD score and the tendon score were significant with hazard ratio of 1.14 (95% CI, 1.08-1.21) and 1.37 (95% CI, 1.13-1.66), respectively. However, among the relapse group, 11 in 20 patients (55%) had a PD score of 0 on US finding before relapse.

Conclusion: The US findings suggest that an elevated PD and tendon score are associated with flare after bDMARDs discontinuation, although it is insufficient for the flare prediction.


Disclosures: T. Ogura, AbbVie/Abbott, Bristol-Myers Squibb(BMS), Eli Lilly, Janssen, Eisai, Asahi kasei; T. Katagiri, None; Y. Takakura, None; C. Imaizumi, None; H. Kameda, AbbVie, Asahi-Kasei, Lilly, Janssen, Novartis, Sanofi, Bristol-Myers Squibb, Chugai, Mitsubishi Tanabe, Eisai, Astellas, Gilead, Taisho.

To cite this abstract in AMA style:

Ogura T, Katagiri T, Takakura Y, Imaizumi C, Kameda H. Time-course Ultrasonography to Predict Flare After Discontinuation of Biologics in Patients with Rheumatoid Arthritis Achieving Stringent Remission [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/time-course-ultrasonography-to-predict-flare-after-discontinuation-of-biologics-in-patients-with-rheumatoid-arthritis-achieving-stringent-remission/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/time-course-ultrasonography-to-predict-flare-after-discontinuation-of-biologics-in-patients-with-rheumatoid-arthritis-achieving-stringent-remission/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology